Nurix Therapeutics to Participate in the 22nd Annual Needham Virtual Healthcare Conference

Rhea-AI Summary

Nurix Therapeutics, a clinical-stage biopharmaceutical company focused on targeted protein modulation for treating cancer, announced that President and CEO Arthur T. Sands, M.D., Ph.D., will participate in a fireside chat at the 22nd Annual Needham Virtual Healthcare Conference on April 20, 2023, at 3:00 p.m. ET. The event will be available for live streaming, and an archived version will be accessible on the company's website for 30 days post-event.

Nurix's innovative approach includes the discovery and development of small molecules and cell therapies that modulate cellular protein levels using E3 ligases. Their proprietary DELigase platform enables the identification of novel drug candidates targeting E3 ligases, aimed at treating hematologic malignancies and solid tumors. For more information, visit Nurix's website.

SAN FRANCISCO, April 11, 2023 (GLOBE NEWSWIRE) -- Nurix Therapeutics, Inc. (Nasdaq: NRIX), a clinical-stage biopharmaceutical company developing targeted protein modulation drugs designed to treat patients with hematologic malignancies and solid tumors, today announced that Arthur T. Sands, M.D., Ph.D., Nurix’s president and chief executive officer, will participate in a fireside chat at the 22nd Annual Needham Virtual Healthcare Conference on Thursday, April 20 at 3:00 p.m. ET.

The event will be webcast live and may be accessed via a link in the Investors section of the Nurix website under Events and Presentations. The archived webcast will be available on the Nurix website for 30 days after the event.

About Nurix

Nurix Therapeutics is a clinical stage biopharmaceutical company focused on the discovery, development and commercialization of small molecule and cell therapies based on the modulation of cellular protein levels as a novel treatment approach for cancer and other challenging diseases. Leveraging extensive expertise in E3 ligases together with proprietary DNA-encoded libraries, Nurix has built DELigase, an integrated discovery platform to identify and advance novel drug candidates targeting E3 ligases, a broad class of enzymes that can modulate proteins within the cell. Nurix’s drug discovery approach is to either harness or inhibit the natural function of E3 ligases within the ubiquitin proteasome system to selectively decrease or increase cellular protein levels. Nurix’s wholly owned pipeline includes targeted protein degraders of Bruton’s tyrosine kinase, a B-cell signaling protein, and inhibitors of Casitas B-lineage lymphoma proto-oncogene B, an E3 ligase that regulates activation of multiple immune cell types including T cells and NK cells. Nurix is headquartered in San Francisco, California. For additional information visit http://www.nurixtx.com.

Contacts:

Investors
Silinda Neou
Nurix Therapeutics
ir@nurixtx.com

Elizabeth Wolffe, Ph.D.
Wheelhouse Life Science Advisors
lwolffe@wheelhouselsa.com

Media
Aljanae Reynolds
Wheelhouse Life Science Advisors
areynolds@wheelhouselsa.com 

FAQ

What event is Nurix Therapeutics participating in on April 20, 2023?

Nurix Therapeutics will participate in the 22nd Annual Needham Virtual Healthcare Conference on April 20, 2023.

Who is representing Nurix Therapeutics at the Needham Conference?

Arthur T. Sands, M.D., Ph.D., the President and CEO of Nurix Therapeutics, will represent the company.

At what time is Nurix's session scheduled during the Needham Conference?

Nurix's session is scheduled for 3:00 p.m. ET on April 20, 2023.

How can I access the live webcast of Nurix's conference participation?

The live webcast can be accessed through the Investors section of Nurix's website under Events and Presentations.

Will the webcast be available after the event?

Yes, the archived webcast will be available on Nurix's website for 30 days following the event.